Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)-Reference-Cited by-同舟云学术

Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial)

Published:2017-06 Issue:12 Volume:119 Page:1989-1996
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Balla Somasekhara R.,Cyr Derek D.,Lokhnygina Yuliya,Becker Richard C.,Berkowitz Scott D.,Breithardt Günter,Fox Keith A.A.,Hacke Werner,Halperin Jonathan L.,Hankey Graeme J.,Mahaffey Kenneth W.,Nessel Christopher C.,Piccini Jonathan P.,Singer Daniel E.,Patel Manesh R.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference29 articles.

1. Prevalence and trends in obesity among US adults, 1999-2000;Flegal;JAMA,2002

2. Obesity and cardiovascular disease;Lavie;J Am Coll Cardiol,2009

3. Atrial fibrillation and obesity: results of a meta-analysis;Wanahita;Am Heart J,2008

4. Secular trends in incidence of atrial fibrillation in Olmstead County, Minnesota, 1980-2000 and implications on the projections for future prevalence;Miyasaka;Circulation,2006

5. Obesity and the risk of new-onset atrial fibrillation;Wang;JAMA,2004

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis;Journal of Clinical Medicine;2024-06-27

2. Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK);Clinical and Translational Science;2024-06

3. Obese patients with atrial fibrillation are more efficiently protected from thrombosis under warfarin or xabans compared to non-obese patients; a systematic review and Meta-analysis of six randomized controlled trials;Thrombosis Research;2024-06

4. Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual Patient Data Meta-Analysis of 4 Randomized Clinical Trials of Patients With Atrial Fibrillation;Circulation;2024-03-19

5. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Circulation;2024-01-02